Pre-emptive broad-spectrum treatment for ventilator-associated pneumonia in high-risk patients

2013 ◽  
Vol 39 (9) ◽  
pp. 1547-1555 ◽  
Author(s):  
Emilio Bouza ◽  
María Jesús Pérez Granda ◽  
Javier Hortal ◽  
José M. Barrio ◽  
Emilia Cercenado ◽  
...  
2003 ◽  
Vol 47 (8) ◽  
pp. 2492-2498 ◽  
Author(s):  
Alexander A. Padiglione ◽  
Rory Wolfe ◽  
Elizabeth A. Grabsch ◽  
Di Olden ◽  
Stephen Pearson ◽  
...  

ABSTRACT Accurate assessment of the risk factors for colonization with vancomycin-resistant enterococci (VRE) among high-risk patients is often confounded by nosocomial VRE transmission. We undertook a 15-month prospective cohort study of adults admitted to high-risk units (hematology, renal, transplant, and intensive care) in three teaching hospitals that used identical strict infection control and isolation procedures for VRE to minimize nosocomial spread. Rectal swab specimens for culture were regularly obtained, and the results were compared with patient demographic factors and antibiotic exposure data. Compliance with screening was defined as “optimal” (100% compliance) or “acceptable” (minor protocol violations were allowed, but a negative rectal swab specimen culture was required within 1 week of becoming colonized with VRE). Colonization with VRE was detected in 1.56% (66 of 4,215) of admissions (0.45% at admission and 0.83% after admission; the acquisition time was uncertain for 0.28%), representing 1.91% of patients. No patients developed infection with VRE. The subsequent rate of new acquisition of VRE was 1.4/1,000 patient days. Renal units had the highest rate (3.23/1,000 patient days; 95% confidence interval [CI], 1.54 to 6.77/1,000 patient days). vanB Enterococcus faecium was the most common species (71%), but other species included vanB Enterococcus faecalis (21%), vanA E. faecium (6%), and vanA E. faecalis (2%). The majority of isolates were nonclonal by pulsed-field gel electrophoresis analysis. Multivariate analysis of risk factors in patients with an acceptable screening suggested that being managed by a renal unit (hazard ratio [HR] compared to the results for patients managed in an intensive care unit, 4.6; 95% CI, 1.2 to 17.0 [P = 0.02]) and recent administration of either ticarcillin-clavulanic acid (HR, 3.6; 95% CI, 1.1 to 11.6 [P = 0.03]) or carbapenems (HR, 2.8; 95% CI, 1.0, 8.0 [P = 0.05]), but not vancomycin or broad-spectrum cephalosporins, were associated with acquisition of VRE. The relatively low rates of colonization with VRE, the polyclonal nature of most isolates, and the possible association with the use of broad-spectrum antibiotics are consistent with either the endogenous emergence of VRE or the amplification of previously undetectable colonization with VRE among high-risk patients managed under conditions in which the risk of nosocomial acquisition was minimized.


2011 ◽  
Vol 19 (6) ◽  
pp. 1329-1336 ◽  
Author(s):  
Leandra Terezinha Roncolato da Silva ◽  
Ana Maria Laus ◽  
Silvia Rita Marin da Silva Canini ◽  
Miyeko Hayashida

This study aimed to evaluate the quality of health care delivered in an Intensive Care Unit, concerning the use of pneumonia prevention and control measures in high-risk patients on mechanical ventilation. In this descriptive and exploratory research, 839 observations of patients under invasive ventilation care were carried out, between November 2009 and January 2010, using the Indicator of Evaluation of Adherence to Prevention and Control Measures in High-risk Patients (IRPR). Some isolated measures that compose the mentioned indicator reached rates close to 100%, but the general compliance rate with all prevention and control measures of ventilator-associated pneumonia was 26.94%. It is concluded that, although the evaluated practices are accomplished at the unit, systematic evaluations of the interventions is needed so as to permit the discussion and practice of other educational strategies by the health team.


2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 19623-19623
Author(s):  
K. V. Rolston ◽  
E. Coyle ◽  
R. Prince

19623 Background: Quinolone prophylaxis is recommended in high-risk neutropenic patients. Although effective in reducing the frequency of febrile episodes and documented gram-negative infections, this approach can lead to the emergence of resistant organisms. Surveillance studies looking for changes in resistance patterns at institutions that care for high-risk patients are also recommended. Methods: Our institution has participated in the meropenem yearly susceptibility test information collection (MYSTIC) program since 2000. The susceptibility of E. coli isolates from our cancer patients to quinolones (ciprofloxacin and levofloxacin) and broad-spectrum agents often used in empiric antimicrobial regimens in such patients, was determined. These studies were conducted by JMI Laboratories, Iowa, USA, and combined results as well as results of each participating institution were provided. CLSI designated breakpoints for susceptibility were used. Ribotyping and PFGE studies were performed on recent isolates. Results: Table 1 documents the declining susceptibility of E. coli isolates to the quinolones. In 2006 only 40.7% were quinolone susceptible compared to 84.2% in 2000 (p = 0.0032). All E. coli isolates remain susceptible to the carbapenems (meropenem, imipenem, ertapenem) and 95.5% remain susceptible to cefepime, ceftazidime, piperacillin-tazobactam, and the aminoglycosides. Twenty-one resistant E. coli isolates underwent ribotyping. Fourteen isolates showed identical ribotype and similar PFGE patterns suggesting the presence of an endemic clone. The other 7 isolates showed variability in their molecular patterns. Conclusions: Quinolone resistance among E. coli strains isolated from cancer patients has increased substantially. Fortunately these isolates remain susceptible to most broad-spectrum beta-lactams and aminoglycosides. Effective infection control methods need to be implemented and enforced in order to reduce the spread of these organisms in high risk patients. No significant financial relationships to disclose. [Table: see text]


2020 ◽  
Vol 41 (5) ◽  
pp. 547-552 ◽  
Author(s):  
Cristine C. Lacerna ◽  
Donna Patey ◽  
Lawrence Block ◽  
Sejal Naik ◽  
Yulia Kevorkova ◽  
...  

AbstractObjective:To develop and evaluate a program to presvent hospital-acquired pneumonia (HAP).Design:Prospective, observational, surveillance program to identify HAP before and after 7 interventions. An order set automatically triggered in programmatically identified high-risk patients.Setting:All 21 hospitals of an integrated healthcare system with 4.4 million members.Patients:All hospitalized patients.Interventions:Interventions for high-risk patients included mobilization, upright feeding, swallowing evaluation, sedation restrictions, elevated head of bed, oral care and tube care.Results:HAP rates decreased between 2012 and 2018: from 5.92 to 1.79 per 1,000 admissions (P = .0031) and from 24.57 to 6.49 per 100,000 members (P = .0014). HAP mortality decreased from 1.05 to 0.34 per 1,000 admissions and from 4.37 to 1.24 per 100,000 members. Concomitant antibiotic utilization demonstrated reductions of broad-spectrum antibiotics. Antibiotic therapy per 100,000 members was measured as follows: carbapenem days (694 to 463; P = .0020), aminoglycoside days (154 to 61; P = .0165), vancomycin days (2,087 to 1,783; P = .002), and quinolone days (2,162 to 1,287; P < .0001). Only cephalosporin use increased, driven by ceftriaxone days (264 to 460; P = .0009). Benzodiazepine use decreased between 2014 to 2016: 10.4% to 8.8% of inpatient days. Mortality for patients with HAP was 18% in 2012% and 19% in 2016 (P = .439).Conclusion:HAP rates, mortality, and broad-spectrum antibiotic use were all reduced significantly following these interventions, despite the absence of strong supportive literature for guidance. Most interventions augmented basic nursing care. None had risks of adverse consequences. These results support the need to examine practices to improve care despite limited literature and the need to further study these difficult areas of care.


2001 ◽  
Vol 120 (5) ◽  
pp. A376-A376
Author(s):  
B JEETSANDHU ◽  
R JAIN ◽  
J SINGH ◽  
M JAIN ◽  
J SHARMA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document